Advertise on podcast: Leading Beyond The Lab

If AI is collapsing the cost of healthcare — are we on the brink of a historic breakthrough… or another bubble? This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms. With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences strategy, Edward has been at the forefront of investing where biology, computation, and healthcare collide. In this episode, Edward covers: - What’s genuinely different about AI in drug discovery and digital medicine today, and how collapsing healthcare costs could unlock a $10 trillion opportunity by reshaping long-term global supply–demand dynamics. - Edward explains how @Excelsior, backed by Sofinnova Partners, @Khosla Ventures and @Deerfield Management, and led by @Mike Foley, is using an AI-driven, modular chemistry platform, originating from @Marty Burke at the @University of Illinois, to create entirely new, de novo small-molecule drugs. - Why the US pharma & tech landscape may resemble a bubble, or a once-in-a-generation inflection point - He talks about @Latent Labs, (led by @Simon Kohl) a Sofinnova-backed company designing entirely new proteins that do not exist in nature, unlocking new therapeutic possibilities. - Edward outlines Sofinnova’s investment in @Bioptimus and discusses @Moon Surgical, exploring how AI and robotics are improving drug discovery and augmenting clinicians in complex procedures. - Edward reflects on the broader AI landscape, referencing an @HSBC investment banking report questioning the long-term economics underpinning large AI models such as @OpenAI, before highlighting comments from @Geoffrey Hinton on the scalability limits of current AI architectures. From AI-driven drug discovery and robotics in surgery, to healthcare economics, venture capital philosophy, and Europe vs the US innovation gap, this is a deep, unfiltered look at where life sciences is heading next. To listen to (or watch) the full episode, search "Leading Beyond The Lab Edward Kliphuis" on your preferred streaming platform, or click on the first link in the comments below! Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Youtube: https://www.youtube.com/@life_sciences Website: https://arto-talent.com Edward Kliphuis Partner at Sofinnova Partners LinkedIn: https://www.linkedin.com/in/ekliphuis/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Sofinnovas Partner's Investments 17:41 The US Pharma "Bubble" & AI 28:02 Investing in the Right CEO / Company Hosted on Acast. See acast.com/privacy for more information.

From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options? This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development. A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry. In this episode, Amit covers: • How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09) • What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29) • The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58) • Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37) • Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00) If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time. Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders. Follow ARTO: https://linktr.ee/arto_talent Amit Rakhit LinkedIn: https://www.linkedin.com/in/amit-rakhit/ Lawrence Rose LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction and background 01:09 Cell therapy and BlueRock Therapeutics’ mission 03:29 Leadership, credibility, and execution 04:58 CEO vs CMO roles in biotech 06:37 Authenticity, inclusion, and culture 09:24 What separates successful biotechs 12:00 Physician scientists transitioning into industry 18:34 Career-defining moments and resilience 22:38 The future of cell therapy and emerging modalities 24:32 AI in drug discovery and clinical development 26:26 Closing thoughts and where to connect #LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment Hosted on Acast. See acast.com/privacy for more information.

97% of our viewers don't realise they aren't followed, please double check, thank you! What does it really take to back and build world-class biotech companies from idea to FDA approval? This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital. With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US. In this episode Jonathan covers: - How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK. - Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades. - Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes. - Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds. - How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds. - Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle. Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech. To listen to (or watch) the full episode, search "Leading Beyond The Lab Jonathan Tobin" on your preferred streaming platform. Hosted on Acast. See acast.com/privacy for more information.

This episode is a masterclass in how world-class life sciences investors think about risk, conviction, and real patient impact. This week on Leading Beyond The Lab, Lawrence Rose sat down with Nikhil Thatte, Partner at Lumira Ventures, a leading Canadian life sciences venture capital firm, with over a decade of experience backing transformative biotech and medtech companies across North America. In this conversation, Nikhil shares how Lumira Ventures has built a top-quartile VC track record over multiple market cycles, investing across therapeutic areas including oncology, gene editing, gene therapy, immunology, cardiometabolic disease, and medical devices. He also reflects on his journey helping scale globally impactful healthcare companies while staying grounded in patient outcomes. In this episode, Nikhil covers: • How Lumira Ventures evaluates investment opportunities in today’s biotech market, including why clinical data, valuation discipline, and a clear path to liquidity now matter more than ever (08:38) • Lessons from Lumira’s major exit successes, including Histosonics and Endotronix, and what made these companies stand out from an investor perspective, with insights into leadership, timing, and execution alongside Mike Blue at Histosonics (02:33) • What truly differentiates exceptional founders and management teams, with real examples of conviction moments backing leaders such as Joanna Stanicka at Axonis and Jade Doucet-Martineau at Puzzle Med (22:08) • Why Canada punches above its weight in life sciences innovation, the structural challenges holding the ecosystem back, and what must change to retain value domestically, including reflections on Canadian success stories discussed throughout the episode (17:40) • The vision behind the Cancer Breakthrough Fund, Lumira’s partnership with the Terry Fox Foundation, and how this model brings new capital, clinical expertise, and impact-driven investors into oncology innovation (31:08) If you want a rare, honest look inside how top life sciences VCs assess opportunity, leadership, and long-term value creation, this is an episode you don’t want to miss. Follow ARTO: https://linktr.ee/arto_talent Nikhil Thatte LinkedIn: https://www.linkedin.com/in/nikhil-thatte-72372333/ Lawrence Rose Director at ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction to Nikhil Thatte and Lumira Ventures 02:33 Major exits including Histosonics and Endotronix 05:30 Fund V and what drives LP conviction today 08:38 How Lumira evaluates deals in the current biotech market 17:40 Canada’s competitive advantages and ecosystem challenges 22:08 Backing exceptional founders and leadership teams 31:08 The Cancer Breakthrough Fund and Terry Fox Foundation partnership 37:00 Technologies and trends shaping the next 5–10 years 41:16 Patient impact and what ultimately motivates long-term investing #LeadingBeyondTheLab #ARTOTalent #LifeSciences #BiotechVC #Medtech #VentureCapital #CanadianInnovation Hosted on Acast. See acast.com/privacy for more information.

Cardio-metabolic diseases are the world’s biggest killer. But what if the next generation of treatments could change everything? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jyothis George, CMO of Nodthera, and a global thought leader in the obesity space, shaping the future of cardio-metabolic and inflammatory disease innovation. Jyothis has led global programs across GLP-1, SGLT2, PCSK9 and now the emerging NLRP3 inhibitor class. His work spans companies such as Novo Nordisk, Amgen, Boehringer Ingelheim and his move into biotech with NodThera marks a shift from big-Pharma leadership into next-wave therapeutic development. In this episode, Jyothis covers: - How NodThera is shaping the future of metabolic and inflammatory disease treatment. - A look at the mindset and challenges behind leading in a high-stakes biotech environment. - Why the right investors often play a critical mentorship role in biotech growth. - Exploring why endocrinology remains underfunded and overlooked in biotech circles. - How he previously worked with Eli Lilly (led by David Ricks), contributing to their efforts in the cardiometabolic space. - Reflections on personal legacy, long-term impact, and how to get in touch. If you’re interested in cardio-metabolic innovation, GLP-1 evolution, biotech strategy or leadership at the cutting edge of science, this episode is worth your time. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Jyothis George CMO at NodThera LinkedIn: https://www.linkedin.com/in/jyothisgeorge/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 01:40 NodThera's Role in Future Endocrinology 10:48 Leadership in Biotech 21:05 Investment and Mentorship 30:58 Endocrinology's Underinvestment 38:13 Jyothis George: Legacy & Contact Hosted on Acast. See acast.com/privacy for more information.

25 years of life sciences venture experience in one episode. This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His track record includes multiple successful exits, advising boards, working across Medtech, Biotech, digital health and Techbio, and supporting companies through regulatory approval, clinical development and commercial scale. In this episode, Joey covers: Joey dives into his career spanning 25 years of Life Sciences experience, from early biotech to leading global investment firms.He unpacks the frameworks and philosophies that guide his investment decisions across the Life Sciences ecosystem.Joey reflects on a standout investment, what made it succeed, and the lessons it offers future founders.A candid discussion on what strong leadership looks like in high-growth Life Sciences ventures.Joey shares exactly what he looks for in a pitch, and what turns him off instantly.Looking ahead, Joey reveals where he’s placing bets and what excites him most about the next wave of Life Sciences innovation. Check out this episode if you want a grounded, practical understanding of how life sciences companies are assessed, funded and supported behind the scenes, and how founders can communicate, hire and plan more effectively on the path to scale. Follow ARTO! LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Lawrence Rose Co-Founder + Talent Solutions Director at @ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Joey Mason Venture Advisor @Sofinnova Venture Partner @Claret Capital Partners LinkedIn: https://www.linkedin.com/in/joey-mason/ Timestamps 01:09 Joey’s Career 05:14 Investment approaches 19:17 Most successful investment 28:20 Leadership 32:46 How to pitch to Joey Mason 42:21 Future plans #LeadingBeyondTheLab #ARTOTalent #LifeSciences #VentureCapital #VentureDebt #Medtech #Biotech #TechBio #DigitalHealth #IrelandEcosystem #Pharma #InvestmentStrategy Hosted on Acast. See acast.com/privacy for more information.

🤔 What does it really take to build a biotech that survives the clinical gauntlet and scales into a global business? 🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited. Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from inception through clinical development, commercial launch and manufacturing scale-up. Along the way he references outcomes from portfolio companies such as Autolus Therapeutics and Beacon Therapeutics, showing how patient capital and conviction-led strategy compound over time. ⭐️ Syncona has an impressive portfolio including, Autolus Therapeutics, Beacon Therapeutics, Spur Therapeutics, iOnctura, Quell Therapeutics, ANAVEON AG, MOSAIC THERAPEUTIC SERVICES, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics. 🚀 In this episode, Roel dives into: - What defines a Syncona company and its unique model - Key lessons learned from both successes and setbacks - How to manage investor involvement without stifling progress - The challenges of leadership transitions within portfolio companies - Syncona’s strategic commitment to the European market - What drives Roel personally and what he enjoys most about his role Check out this episode if you want grounded insight into biotech venture building, long-term capital strategy and how scientific founders scale from the lab to patient impact. 🤝 Follow ARTO! LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Lawrence Rose Co-Founder + Talent Solutions Director at @ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Role Bulthuis Managing Partner @Syncona LinkedIn: https://www.linkedin.com/in/roel-bulthuis-aa414a/ Timestamps: 01:10 What makes up a Syncona company? 11:25 What were the main lessons learnt from previous failures/successes? 15:06 Managing investor involvement & preventing counter productivity. 22:14 The issues with exchanging leadership. 31:07 Commitment to the European Market. 42:20 What Roel enjoys about his job. Hosted on Acast. See acast.com/privacy for more information.

A once-in-a-century transformation, and the leader driving it. This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history. With over 25+ years of global biopharma leadership experience, spanning pivotal roles at Amgen, Sanofi, and Orphazyme, Christophe brings a rare combination of commercial excellence, turnaround leadership, and global market insight. He also shares how senior leaders such as Murdo Gordon helped shape his approach to building high-performing, people-centric teams. In this episode, Host of Leading Beyond The Lab, @Lawrence Rose, discusses with Christophe how he’s reshaping a century-old European company into a modern, innovation-driven global leader, covering: Transforming LEO Pharma, from financial urgency to sustainable growth, cultural renewal, and long-term clarity.The Partner and Development model, and why global players like Gilead Sciences and Boehringer Ingelheim have chosen LEO as a trusted innovation partner.Leadership and culture at scale, transparency, conviction, rebuilding confidence, and empowering bold talent.Preparing for a future IPO, aligning profitability, growth, and a clear 5-year vision for employees, shareholders, and partners.Europe vs. the US in the next decade of biotech, why the US has become LEO’s largest affiliate and what this shift means for global competitiveness. This episode is a rare look at what it truly takes to modernise a legacy company while keeping innovation, collaboration, and leadership at the core. Be sure to check out this episode - one of our most important conversations to date. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Christophe Bourdon CEO of LEO Pharma LinkedIn: https://www.linkedin.com/in/christophe-bourdon-77a62b6/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 LEO’S Recent Achievements 06:58 Shaping a Modern LEO Pharma 16:30 LEO Pharma’s IPO Journey 25:39 Christophe’s Leadership Hosted on Acast. See acast.com/privacy for more information.

What does it take to shape a high-impact biotech investment portfolio - and do it under a medical charity mandate? This week we sit down with Clare Terlouw, Head of LifeArc Ventures, whose 20+ year career spans investment banking, biotech company building, and leading venture teams focused on health innovation. With a unique perspective at the intersection of science, capital, and patient impact, Clare shares a candid and optimistic view of the evolving biotech landscape in the UK and beyond. In this episode, Clare covers: - LifeArc Ventures’ mission: how a medical charity is driving returns while staying true to a patient-first vision. - Investing and scaling biotech: from early inflection points to Series B and beyond, what great companies get right. - Biotech in the UK: challenges in the current funding environment, the talent surge, and why optimism still holds. - Tech-enabled drug discovery: how AI, computational biology, and new business models are shaping investment priorities. - Clare's leadership lens: her personal drive, how she evaluates opportunity, and the power of staying focused on patient outcomes. Be sure to check out this episode if you're interested in the future of biotech investing, the rise of tech-enabled therapeutics, and how one venture leader is backing science that matters. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Clare Terlouw Managing Partner at Life Arc LinkedIn: https://www.linkedin.com/in/clare-terlouw-b608aa17/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Life Arc - Investments + Impact 09:44 Investing in and Growing a Company 17:52 Biotech in the UK 26:18 Tech Enabled Drug Discovery 32:57 Clare Terlouw Hosted on Acast. See acast.com/privacy for more information.

If you're not paying attention to nuclear medicine, Danielle Meyrick will change that in under five minutes. This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as both a scientific pioneer and commercial strategist. Her career has spanned from launching radiopharmaceutical therapies in hospitals to shaping global strategies for biotech companies. If you're serious about understanding the future of oncology, this is the episode to watch. In this episode we cover: Why nuclear medicine is having a moment - and what makes radiotheranostics the most promising modality in oncology today.From PhD to MD – Danielle’s unconventional path to medicine, and how her dual perspective shaped her leadership style.What it takes to commercialise complex therapies – lessons from inside large pharma, mid-stage biotechs, and early-stage ventures.The clinical data that changed everything – and how early adopters leveraged compassionate use to gain momentum.What’s next for EPIC Theranostics – and why workforce readiness and isotope supply could make or break the sector. If you're in biotech, pharma, or medtech, this episode is a masterclass in strategic thinking and scientific depth. Watch now and get ahead of where oncology is going. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Danielle Meyrick Co-Founder + Director At EPIC Theranostiocs LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 06:12 Nuclear Medicine 09:26 Characteristics of a Good Drug Developer 14:13 Future of Radiotheranostics 20:05 Approaching Challenges 26:52 Advice 29:25 Motivations 30:56 Greatest Achievements #LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

Two of the most influential minds in immuno-oncology walk into a biotech… and build something that could change everything. Dr. Rachel Humphrey (CEO) and Dr. Melinda Merchant (CMO) of Normunity are two of the most seasoned and respected leaders in oncology drug development, with a combined 45+ years of experience across big pharma, biotech, and translational science. Rachel led the development of Yervoy® (ipilimumab) at BMS, Imfinzi® (durvalumab) at AstraZeneca, and Nexavar® (sorafenib) at Bayer, before holding CMO roles at Black Diamond, Mirati, and CytomX. Melinda, an immunologist and dual board-certified pediatric oncologist, spent a decade leading clinical studies at NIH and Memorial Sloan Kettering, running early trials of ipilimumab, nivolumab, and novel cell therapies before moving to industry and leading clinical development efforts of multiple investigational new drugs. Together, they now lead Normunity, where they’re pioneering a bold new therapeutic category: immune normalizers - designed to unlock immune resistance and open up new frontiers in cancer treatment.In this episode, we cover: - How Normunity is redefining immuno-oncology with its first-in-class T-cell engager - What it takes to build scientific teams that challenge each other - and still move fast - Lessons from launching Yervoy, Imfinzi, Tazverik, and other breakthrough therapies - Why biotech culture needs both humility and ego to succeed - What’s next as Normunity prepares to enter the clinic with NRM-823 If you're a life sciences leader, founder, or investor - this conversation is essential listening. Tap in to hear what it really takes to build, lead, and scale science that matters. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Rachel Humphrey CEO at Normunity LinkedIn: https://www.linkedin.com/in/rachel-w-humphrey-md-116b211b/ Melinda Merchant CMO at Normunity LinkedIn: https://www.linkedin.com/in/melinda-merchant-7b496a/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 16:58 Traits of a Drug Developer 19:53 Leadership in Biotech 27:28 Story Behind Normunity 30:23 Normunity Culture 32:28 Mindsets in Translational Science 36:33 Personal Life #LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.

Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of experience across translational science, drug development and leadership in global R&D. His conviction, clarity, and track record - including developing molecules that have become partnered, acquired and approved - makes this conversation a must-listen for anyone in life sciences leadership. In this episode, we cover: How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseasesWhy conviction, speed, and storytelling are non-negotiable in translational drug developmentLessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnershipsWhat investors really look for - and how Maxion secured a competitive Series A in a tough marketHow to hire and scale for scientific excellence without losing agility or collaboration Tune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Arndt Schottelius CEO at Maxion Theraprutics LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 06:46 Translational Science 08:55 Lessons in Biotech Leadership 25:23 Maxion - Culture and Roundup #LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you want to understand what it really takes to build and lead a successful biotech, this episode is for you. Dr. Christopher Morabito, Chief Medical Officer at Astria Therapeutics, joins us to share hard-won lessons from 25 years in rare disease, oncology, and immunology. But this isn’t a career retrospective - it’s a deep dive into the mindset, strategies, and leadership habits that drive biotech success. In this episode, Chris reveals: How to make tough go/no-go decisions when the data isn’t clear.The leadership traits that keep teams aligned, motivated, and resilient in high-pressure environments.Why clarity of purpose matters more than anything else in a biotech’s mission.How to navigate the tension between scientific ambition and commercial reality.The patterns he’s seen across programs that make it from idea to approval. Chris distills decades of experience into practical, actionable advice for founders, executives, and investors - making this one of the most insightful conversations we’ve had yet. 🎧 Tune in for a rare, candid look at biotech leadership from someone who’s been on the front lines of game-changing therapies. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Christopher Morabito CMO at Astria Therapeutics LinkedIn: https://www.linkedin.com/in/chrismorabito/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 13:40 Moving Into Biotech 23:34 Leading in Biotech 28:41 Patients First 38:23 Lessons & Legacy #LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for. We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene. In this episode, Bhaskar dives deep into: · How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology. · What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference. · Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials. · Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis. · Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science. 🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Bhaskar Srivastava CMO at Triveni Bio LinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 15:44 Success & Growth in Biotech 28:43 Investing in Biotech 34:23 The Future of Dermatology & Triveni Bio #LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you care about the future of genomics, diagnostics, and biotech investing, you can’t miss this episode. We’re joined by Mara Aspinall, Partner at Illumina Ventures, a trailblazer with over 30 years of leadership in diagnostics and eight years in venture capital funding groundbreaking genomics companies. In this episode, Mara reveals: The next wave of diagnostics, from liquid biopsies to home testing and new AI-driven tools.Hard-won lessons from leading Genzyme Genetics, Roche Tissue Diagnostics, and building her own startup.Insider tips for founders on pitching, choosing the right investors, and building winning teams.A glimpse into where genomics is heading in the next decade - from neurodegenerative disease detection to early metabolic disease diagnostics.With her unmatched experience as an operator, educator, and investor, Mara brings clarity, energy, and vision to a fast-changing field. This conversation is packed with takeaways for founders, investors, and anyone fascinated by the future of healthcare. 🎧 Tune in now for a masterclass in diagnostics, genomics, and venture capital from one of the industry’s most influential voices. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: Leading Beyond The Lab Instagram: Instagram (@arto.talent) TikTok: artotalent on TikTok Apple Podcasts: Leading Beyond The Lab Website: Home Youtube: ARTO Recruitment Mara Aspinall Partner At Illumina Ventures LinkedIn: https://www.linkedin.com/in/mara-aspinall-6688142/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Career Beginnings 04:10 Current Diagnostic Trends 20:48 The Founder Investor Fit 25:37 Genetics & Genomics 29:06 Mara Aspinall 39:31 Neurodegenerative Disease #LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.